Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis
- PMID: 17213872
- DOI: 10.1038/sj.ejcn.1602582
Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis
Abstract
Objective: To compare the performance of recently released body mass index percentiles (BMIp) with standard anthropometric indexes, including height-for-age percentile (HAP), weight-for-age percentile (WAP) and percent ideal body weight (%IBW), as measures for nutritional failure in children with cystic fibrosis (CF).
Design: Cross-sectional analysis of growth and lung function data from 4577 children with CF reported to the German CF quality assurance (CFQA) project from 1995 to 2004.
Results: Frequency distribution of HAP (mean+/-s.d.: male 30.0+/-27.5; female 31.3+/-27.4) and WAP (male 28.9+/-27.0; female 29.6+/-26.7) were skewed, with significant numbers of patients below the fifth percentiles of a healthy reference population. However, because deficits occurred in both measures simultaneously, mean %IBW (male 97.0+/-12.1; female 98.1+/-12.3) assumed subjects weight close to the nominal weight-for-height at all ages. In contrast, mean BMIp was markedly reduced (male 35.7+/-27.9; female 35.6+/-27.2) and steadily declined with age. Ideal weight-for-age was significantly lower when predicted by %IBW compared with BMIp method, particularly in subjects with shorter-than-average stature. Consequently, less CF children were identified with nutritional failure according to %IBW method (male 20.5%; female 22.7%) compared with BMIp method (male 30.4%; female 28.7%). The clinical relevance of these findings was confirmed by stronger correlation of BMIp with impaired %forced expiratory volume/s, a marker for disease progression in CF.
Conclusion: BMIp predicts nutritional failure more sensitively and accurately than conventional anthropometric indexes, at least in children with CF. Screening of CF patients by BMIp could provide an early warning sign and allow for timely therapeutic intervention.
Similar articles
-
Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study.J Pediatr Gastroenterol Nutr. 2009 Sep;49(3):335-42. doi: 10.1097/MPG.0b013e31818f0a39. J Pediatr Gastroenterol Nutr. 2009. PMID: 19543116
-
Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis.J Cyst Fibros. 2009 Jul;8(4):238-44. doi: 10.1016/j.jcf.2009.03.004. Epub 2009 May 5. J Cyst Fibros. 2009. PMID: 19419910
-
Comparison of the use of body mass index percentiles and percentage of ideal body weight to screen for malnutrition in children with cystic fibrosis.Am J Clin Nutr. 2004 Oct;80(4):982-91. doi: 10.1093/ajcn/80.4.982. Am J Clin Nutr. 2004. PMID: 15447909
-
An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth.J Cyst Fibros. 2010 Mar;9(2):75-83. doi: 10.1016/j.jcf.2009.11.002. Epub 2009 Dec 2. J Cyst Fibros. 2010. PMID: 19955022 Review.
-
Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe.J Pediatr. 2005 Sep;147(3 Suppl):S15-20. doi: 10.1016/j.jpeds.2005.08.009. J Pediatr. 2005. PMID: 16202775 Review.
Cited by
-
Recombinant growth hormone therapy for cystic fibrosis in children and young adults.Cochrane Database Syst Rev. 2018 Dec 17;12(12):CD008901. doi: 10.1002/14651858.CD008901.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Aug 23;8:CD008901. doi: 10.1002/14651858.CD008901.pub5. PMID: 30557452 Free PMC article. Updated.
-
Recombinant growth hormone therapy for cystic fibrosis in children and young adults.Cochrane Database Syst Rev. 2021 Aug 23;8(8):CD008901. doi: 10.1002/14651858.CD008901.pub5. Cochrane Database Syst Rev. 2021. PMID: 34424546 Free PMC article.
-
Influences of exocrine pancreatic insufficiency on nutrient digestibility, growth parameters as well as anatomical and histological morphology of the intestine in a juvenile pig model.Front Med (Lausanne). 2022 Sep 9;9:973589. doi: 10.3389/fmed.2022.973589. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36160141 Free PMC article.
-
Genetic modifiers of nutritional status in cystic fibrosis.Am J Clin Nutr. 2012 Dec;96(6):1299-308. doi: 10.3945/ajcn.112.043406. Epub 2012 Nov 7. Am J Clin Nutr. 2012. PMID: 23134884 Free PMC article.
-
A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.Paediatr Drugs. 2007;9 Suppl 1:21-31. doi: 10.2165/00148581-200709001-00004. Paediatr Drugs. 2007. PMID: 17536872 Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical